공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

천식 : 세계 의약품 예측과 시장 분석(-2029년)

Asthma - Global Drug Forecast and Market Analysis to 2029

리서치사 GlobalData
발행일 2020년 12월 상품 코드 979397
페이지 정보 영문 123 Pages
가격
US $ 10,995 ₩ 12,771,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 25,543,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 38,315,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


천식 : 세계 의약품 예측과 시장 분석(-2029년) Asthma - Global Drug Forecast and Market Analysis to 2029
발행일 : 2020년 12월 페이지 정보 : 영문 123 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

천식은 일반적인 만성 폐질환이며, 소아기 발병이 가장 많고, 어느 연령대에서나 발병할 가능성이 있습니다. 만성적인 염증과 그에 따른 기도 협착이 특징이며, 폐를 통한 공기의 통과를 방해합니다. 천식은 지속성 또는 단속성을 띠는 경우가 있고, 중증도 또한 여러가지입니다. 천식 치료에는 단계적인 접근이 존재하며, 질병 중증도가 높아짐에 따라 치료 레벨이 상승합니다. 천식이 매우 불균일한 질환이기 때문에 이러한 표적치료에도 다양한 종류가 있고, 그 중 일부는 현재 후기 단계 파이프라인에 있습니다. 3제 흡입요법은 중등도-중증의 천식 환자에 대해 적합율을 높이기 때문에 예측기간 동안 환자 점유율이 증가할 것으로 예측됩니다.

시판/후기 파이프라인 천식(Asthma) 치료제 시장 예측에 대해 다루었습니다. 또 천식 환자를 중증도별로 분류하여 2019년을 기준년도로 2020-2029년간 예측을 정리했습니다.

목차

제1장 목차

  • 표 리스트
  • 그림 리스트

제2장 천식 : 개요

  • 천식 시장은 예측기간 동안 보수적 성장을 나타낼 것
  • GlaxoSmithKline과 AstraZeneca가 선도
  • 중증 천식 환자를 위한 진단과 치료 옵션을 둘러싼 충족되지 않은 욕구
  • 후기 파이프라인은 편이성이 높은 맞춤형 의약품 요구를 해결
  • 의사의 견해

제3장 서론

  • 성장 촉진요인
  • 관련 보고서
  • 발간 예정인 관련 보고서

제4장 질병 개요

  • 병인과 병태생리학
    • 병인
    • 병태생리학
  • 질병 중증도 분류

제5장 역학

  • 질병의 배경
  • 위험인자와 동반질환
  • 세계 동향 및 역사적 동향
  • 예측 조사 방법
    • 소스
    • 예측의 전제조건과 방법
  • 천식 역학 예측(2019-2029년)
    • 천식 생애 진단 유병률
    • 천식 생애 진단 유병률 : 연령별
    • 천식 생애 진단 유병률 : 성별
    • 천식 생애 진단 유병률 : 중증도별
  • 논의
    • 역학 예측 인사이트
    • 분석의 한계
    • 분석의 강점

제6장 질병 관리

  • 진단과 치료 개요
    • 진단
    • 치료 가이드라인과 임상 진료
  • 미국
  • EU 5개국
  • 일본

제7장 경쟁력 평가

  • 개요

제8장 요구와 기회 평가

  • 개요
  • 정확한 진단
  • 중증 천식을 위한 맞춤 치료법
  • 환자 적합성 향상
  • 치료비 절감

제9장 파이프라인 평가

  • 개요
  • 임상 개발에서 유망한 의약품
    • Thymic Stromal Lymphopoietin Inhibitors
    • CRTH2 Antagonist
    • Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist
  • 기타 개발 중인 의약품

제10장 현재 및 향후 기업

  • 개요
  • 기업 전략 동향
  • AstraZeneca
  • Novartis
  • Roche/Genentech
  • GlaxoSmithKline
  • Teva
  • Boehringer Ingelheim
  • Merck
  • Chiesi
  • Regeneron/Sanofi
  • AB Science SA

제11장 시장 전망

  • 세계 시장
    • 예측
    • 성장요인과 장애물 : 세계 문제
  • 미국
    • 예측
    • 중요 이벤트
    • 성장요인과 장애물
  • EU 5개국
    • 예측
    • 중요 이벤트
    • 성장요인과 장애물
  • 일본
    • 예측
    • 중요 이벤트
    • 성장요인과 장애물

제12장 부록

LSH 21.01.08

List of Tables

List of Tables

  • Table 1: Asthma: Key Metrics in the 7MM
  • Table 2: Classification of Asthma by Severity
  • Table 3: Risk Factors and Comorbidities for Asthma
  • Table 4: Treatment Guidelines for Asthma across the 7MM
  • Table 5: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 6: Country Profile - US
  • Table 7: Country Profile - 5EU
  • Table 8: Country Profile - Japan
  • Table 9: Leading Treatments for Asthma, 2020
  • Table 10: AstraZeneca's Asthma Portfolio Assessment, 2020
  • Table 11: Novartis' Asthma Portfolio Assessment, 2020
  • Table 12: Roche/Genentech Asthma Portfolio Assessment, 2020
  • Table 13: GlaxoSmithKline's Asthma Portfolio Assessment, 2020
  • Table 14: Teva's Asthma Portfolio Assessment, 2020
  • Table 15: Boehringer Ingelheim's Asthma Portfolio Assessment, 2020
  • Table 16: Merck's Asthma Portfolio Assessment, 2020
  • Table 17: Chiesi's COPD Portfolio Assessment, 2019
  • Table 18: Regeneron/Sanofi's Asthma Portfolio Assessment, 2020
  • Table 19: AB Science Asthma Portfolio Assessment, 2020
  • Table 20: Asthma Market - Global Drivers and Barriers, 2019-2029
  • Table 21: Key Events Impacting Sales for Asthma in the US, 2019-2029
  • Table 22: Asthma Market - Drivers and Barriers in the US, 2019-2029
  • Table 23: Key Events Impacting Sales for Asthma in the 5EU, 2019-2029
  • Table 24: Asthma Market - Drivers and Barriers in the 5EU, 2019-2029
  • Table 25: Key Events Impacting Sales for Asthma in Japan, 2019-2029
  • Table 26: Asthma Market - Global Drivers and Barriers in Japan, 2019-2029
  • Table 27: Key Historical and Projected Launch Dates for Asthma
  • Table 28: Key Historical and Projected Patent Expiry Dates for Asthma
  • Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for Asthma in 2019 and 2029
  • Figure 2: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for Asthma, 2020

Asthma - Global Drug Forecast and Market Analysis to 2029

Asthma is a common chronic lung disease that most often develops during childhood, although it can occur at any age. It is characterized by chronic inflammation and subsequent narrowing of the airways, which obstructs the passage of air through the lungs. Asthma can be persistent or intermittent, and also varies in severity. The treatment of asthma involves a step-wise approach, where the level of therapy increases as the disease severity increases. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies, of which some are currently in the late-stage pipeline. Triple inhaled therapies are forecasted to grow in patient share over the forecasted period to increase compliance rates amongst moderate to severe asthma patients.

This model covers the market forecast for the marketed and late-stage pipeline asthma therapeutics. The model segments asthma patients by severity. The base year of this model is 2019, and the forecast period is 2020-2029.

Key Highlights

  • The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the asthma market include high genericization of historical drug classes.
  • Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.
  • The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of asthma in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for asthma? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the asthma market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

  • Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global asthma therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Asthma: Executive Summary

  • 2.1 Asthma Market to Experience Conservative Growth Over the Forecast Period
  • 2.2 GlaxoSmithKline and AstraZeneca Lead the Way
  • 2.3 Unmet Needs Remain Surrounding Asthma Diagnosis and Treatment Options for Severe Patients
  • 2.4 Late-Stage Pipeline Addresses Needs for Personalized and Convenient Medications
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification of Disease Severity

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for Asthma (2019-2029)
    • 5.5.1 Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma
    • 5.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
    • 6.1.1 Diagnosis
    • 6.1.2 Treatment Guidelines and Clinical Practice
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview

8 Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Accurate Diagnosis
  • 8.3 Personalized Therapies for Severe Asthma
  • 8.4 Increased Patient Compliance
  • 8.5 Lower Cost of Therapy

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 Thymic Stromal Lymphopoietin Inhibitors
    • 9.2.2 CRTH2 Antagonist
    • 9.2.3 Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist
  • 9.3 Other Drugs in Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 AstraZeneca
  • 10.4 Novartis
  • 10.5 Roche/Genentech
  • 10.6 GlaxoSmithKline
  • 10.7 Teva
  • 10.8 Boehringer Ingelheim
  • 10.9 Merck
  • 10.10 Chiesi
  • 10.11 Regeneron/Sanofi
  • 10.12 AB Science SA

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers

12 Appendix

Back to Top
전화 문의
F A Q